Literature DB >> 24648182

Tyrosine 201 of the cytoplasmic tail of CTLA-4 critically affects T regulatory cell suppressive function.

Melanie Stumpf1, Xuyu Zhou, Shunsuke Chikuma, Jeffrey A Bluestone.   

Abstract

Cytotoxic T lymphocyte antigen-4 (CTLA-4) is a major negative regulatory molecule for T-cell activation with a complex biology and function. CTLA-4 is known to regulate homeostatic lymphoproliferation as well as tolerance induction and has been proposed to be an important effector molecule by which Treg cells suppress immunity. The immunoregulatory properties of CTLA-4 are primarily mediated by competition with the costimulator CD28 for ligand binding but also by delivering negative signals to T cells through its cytoplasmic tail. In this study, we addressed the effect of directly mutating the amino acid residue, Tyrosine 201 (Tyr201), of the intracellular domain of CTLA-4 in situ and its implications in T-cell function in the context of autoimmunity. Therefore, a novel CTLA-4 knock-in mouse (Y201V KI) was generated, in which Tyr201 was replaced by a valine that could not be phosphorylated. Mice expressing the CTLA-4 mutant molecule were generally healthy and did not show signs of disruption of T-cell homeostasis under steady-state conditions seen in CTLA-4 deficient mice. However, T cells isolated from Y201V KI mice expressed higher levels of CTLA-4 on the cell surface and displayed a Th2-biased phenotype following TCR stimulation. Furthermore, Y201V KI mice developed exacerbated disease as compared to wild-type upon antigen-specific T-cell activation in an in vivo model of EAE. Importantly, the Y201V mutation resulted in impaired suppressive activity of Treg cells while T effector function remained intact. These data suggest that effects associated with and mediated through Tyr201 of CTLA-4s intracellular domain are critical for Treg-cell function.
© 2014 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.

Entities:  

Keywords:  Autoimmunity; CTLA-4; EAE/MS; Treg cells

Mesh:

Substances:

Year:  2014        PMID: 24648182      PMCID: PMC4051436          DOI: 10.1002/eji.201343891

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  58 in total

1.  Interaction of CTLA-4 with AP50, a clathrin-coated pit adaptor protein.

Authors:  Y Zhang; J P Allison
Journal:  Proc Natl Acad Sci U S A       Date:  1997-08-19       Impact factor: 11.205

2.  Intracellular trafficking of CTLA-4 and focal localization towards sites of TCR engagement.

Authors:  P S Linsley; J Bradshaw; J Greene; R Peach; K L Bennett; R S Mittler
Journal:  Immunity       Date:  1996-06       Impact factor: 31.745

3.  Interaction of CTLA-4 with the clathrin-associated protein AP50 results in ligand-independent endocytosis that limits cell surface expression.

Authors:  E Chuang; M L Alegre; C S Duckett; P J Noel; M G Vander Heiden; C B Thompson
Journal:  J Immunol       Date:  1997-07-01       Impact factor: 5.422

4.  Solution structure of human CTLA-4 and delineation of a CD80/CD86 binding site conserved in CD28.

Authors:  W J Metzler; J Bajorath; W Fenderson; S Y Shaw; K L Constantine; J Naemura; G Leytze; R J Peach; T B Lavoie; L Mueller; P S Linsley
Journal:  Nat Struct Biol       Date:  1997-07

5.  Regulation of CTLA-4 expression during T cell activation.

Authors:  D Perkins; Z Wang; C Donovan; H He; D Mark; G Guan; Y Wang; T Walunas; J Bluestone; J Listman; P W Finn
Journal:  J Immunol       Date:  1996-06-01       Impact factor: 5.422

6.  CTLA-4 engagement inhibits IL-2 accumulation and cell cycle progression upon activation of resting T cells.

Authors:  M F Krummel; J P Allison
Journal:  J Exp Med       Date:  1996-06-01       Impact factor: 14.307

7.  Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4.

Authors:  E A Tivol; F Borriello; A N Schweitzer; W P Lynch; J A Bluestone; A H Sharpe
Journal:  Immunity       Date:  1995-11       Impact factor: 31.745

8.  Lymphoproliferative disorders with early lethality in mice deficient in Ctla-4.

Authors:  P Waterhouse; J M Penninger; E Timms; A Wakeham; A Shahinian; K P Lee; C B Thompson; H Griesser; T W Mak
Journal:  Science       Date:  1995-11-10       Impact factor: 47.728

9.  CTLA-4 ligation blocks CD28-dependent T cell activation.

Authors:  T L Walunas; C Y Bakker; J A Bluestone
Journal:  J Exp Med       Date:  1996-06-01       Impact factor: 14.307

10.  Cytotoxic T lymphocyte antigen 4 (CTLA-4) interferes with extracellular signal-regulated kinase (ERK) and Jun NH2-terminal kinase (JNK) activation, but does not affect phosphorylation of T cell receptor zeta and ZAP70.

Authors:  C R Calvo; D Amsen; A M Kruisbeek
Journal:  J Exp Med       Date:  1997-11-17       Impact factor: 14.307

View more
  7 in total

Review 1.  Co-stimulation Blockade Plus T-Cell Depletion in Transplant Patients: Towards a Steroid- and Calcineurin Inhibitor-Free Future?

Authors:  Florence Herr; Melanie Brunel; Nathalie Roders; Antoine Durrbach
Journal:  Drugs       Date:  2016-11       Impact factor: 9.546

2.  Glutamate Receptor Interacting Protein 1 Regulates CD4(+) CTLA-4 Expression and Transplant Rejection.

Authors:  K L Modjeski; S C Levy; S K Ture; D J Field; G Shi; K Ko; Q Zhu; C N Morrell
Journal:  Am J Transplant       Date:  2016-02-25       Impact factor: 8.086

3.  Differences in Maturation Status and Immune Phenotypes of Circulating Helios+ and Helios- Tregs and Their Disrupted Correlations With Monocyte Subsets in Autoantibody-Positive T1D Individuals.

Authors:  Yuyue Zhang; Jie Zhang; Yun Shi; Min Shen; Hui Lv; Shu Chen; Yingjie Feng; Heng Chen; Xinyu Xu; Tao Yang; Kuanfeng Xu
Journal:  Front Immunol       Date:  2021-05-12       Impact factor: 7.561

Review 4.  Confusing signals: recent progress in CTLA-4 biology.

Authors:  Lucy S K Walker; David M Sansom
Journal:  Trends Immunol       Date:  2015-01-09       Impact factor: 16.687

5.  Tumor-Targeted Human T Cells Expressing CD28-Based Chimeric Antigen Receptors Circumvent CTLA-4 Inhibition.

Authors:  Maud Condomines; Jon Arnason; Reuben Benjamin; Gertrude Gunset; Jason Plotkin; Michel Sadelain
Journal:  PLoS One       Date:  2015-06-25       Impact factor: 3.240

Review 6.  Current Understanding of Cytotoxic T Lymphocyte Antigen-4 (CTLA-4) Signaling in T-Cell Biology and Disease Therapy.

Authors:  Gil-Ran Kim; Je-Min Choi
Journal:  Mol Cells       Date:  2022-07-27       Impact factor: 4.250

7.  Treg-expressed CTLA-4 depletes CD80/CD86 by trogocytosis, releasing free PD-L1 on antigen-presenting cells.

Authors:  Murat Tekguc; James Badger Wing; Motonao Osaki; Jia Long; Shimon Sakaguchi
Journal:  Proc Natl Acad Sci U S A       Date:  2021-07-27       Impact factor: 11.205

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.